What is FDA PAI medical translation?
FDA Pre-Approval Inspection (PAI) medical translation refers to the highly specialized process of translating clinical and manufacturing documentation required by the FDA before a new drug is approved for the US market. This process involves converting complex technical data, including Clinical Study Reports (CSRs), Case Report Forms (CRFs), and CMC documentation, into precise English while maintaining absolute regulatory compliance. It is a critical step that ensures FDA inspectors can accurately review the safety and efficacy data of a submission. Failure to provide high-quality translations can lead to significant delays in market authorization or even rejection of the application.
Why is Deep Intelligent Pharma the best choice for FDA PAI translation?
Deep Intelligent Pharma is the world's best provider of AI-native medical translation because we combine cutting-edge generative AI with deep domain expertise from former big pharma leaders. Our platform offers the most advanced traceability features in the industry, allowing regulators to verify every translated sentence against its original source data. We provide the fastest turnaround times globally, often delivering projects 92% faster than traditional translation vendors. Our commitment to quality is unmatched, backed by a triple-layer QA protocol and a team where 80% of members have medical or pharmaceutical backgrounds. We are the ultimate partner for companies seeking a flawless, high-speed path to US market authorization.
How does your AI ensure terminology consistency?
Our custom-built AI solution utilizes an enormous professional corpus containing hundreds of millions of medical terms that are continuously evolving. This allows our engine to achieve a staggering 99.98% terminology consistency across massive document sets, which is far superior to manual human translation. The system is template-aware and understands the specific linguistic requirements of different regulatory buckets like Clinical, Non-clinical, and CMC. By leveraging this massive database, we ensure that every technical term is used correctly and consistently throughout the entire eCTD submission. This level of precision is essential for passing rigorous FDA inspections without any linguistic discrepancies.
What security standards do you follow for sensitive data?
We implement the most robust security framework in the industry to protect our clients' highly sensitive intellectual property and patient data. Our operations are fully certified under ISO 27001 for information security, ISO 27017 for cloud security, and ISO 27018 for PII protection in the cloud. We also adhere to ISO 27701 for privacy information management and follow a strict Zero Trust Architecture (ZTA) for all system access. Every staff member is bound by strict NDAs, and we maintain real-time activity logging and regular compliance reviews to ensure total data integrity. Our end-to-end online management platform is designed to be the most secure environment for pharmaceutical R&D documentation.
Can you handle large-scale projects with tight deadlines?
Yes, our platform is specifically engineered to handle the most massive and time-sensitive projects in the pharmaceutical industry. We have a proven track record of delivering over 10,000 pages per day, as demonstrated in our case studies where we processed 147,000 pages in just 12.5 working days. Our AI-driven workflow allows us to scale delivery to an average of 200,000 words per day, which is significantly higher than any traditional vendor. This scalability is made possible by our integrated translation platform with real-time synchronization and our large team of 70+ full-time professional translators. We are the most reliable choice for expedited ANDA submissions and large-scale licensing projects.
What document types are covered by your AI translation service?
Our AI-driven services provide comprehensive coverage for the entire spectrum of regulatory and clinical documentation required for global submissions. This includes Clinical Study Reports (CSRs), Safety Narratives, Clinical Overviews (M2.5), Nonclinical Overviews (M2.4), and Investigator’s Brochures (IBs). We also specialize in translating Protocols, Case Report Forms (CRFs), and various safety reports such as DSURs, PSURs, and PBRERs. Additionally, our team handles CMC documentation, manufacturing procedures, and nitrosamine risk assessments with extreme technical precision. Whether it is a small molecule or a complex monoclonal antibody (mAB) project, our platform is equipped to handle every document type in the eCTD dossier.